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1. Introduction 
There are many physiological processes in which 
the calcium-dependent regulator protein calmodulin 
seems to play an important role [l]. Indeed the pro- 
tein has been proposed to be ‘a universal receptor 
of the Ca*+ signal’ in cells. According to this scheme, 
Ca*+ first binds to calmodulin causing a conforma- 
tional change. The active conformer of calmodulin 
then binds to certain enzymes with resultant changes 
in conformation and activity [ 11. 
One experimental approach which has been used 
to show if calmodulin is involved in a particular meta- 
bolic process is to examine the effects of antipsychotic 
phenothiazine drugs such as chlorpromazine and tri- 
fluoperazine, which bind to calmodulin and prevent 
its activation by Ca*+ [2]. However,it has been known 
for a long time that these drugs also have local anes- 
thetic (>lO-’ M), cholinergic blocking, and a-adren- 
ergic blocking activities [3]. In particular, radioligand 
binding studies have shown that chlorpromazine and 
trifluoperazine displace [3H]epinephrine, [3H]norep- 
inephrine, [3H]clonidine and [3H]WB-4101 from 
brain a-adrenergic receptors [4-61. Hence, studies of 
the inhibitory effects of these phenothiazines on the 
actions of ar-adrenergic agonists in tissues should not 
be interpreted as indicating the involvement of cal- 
modulin in ol-adrenergic action without additional in- 
formation such as that presented below. However, 
three examples of such interpretation have appeared 
[7-91. Another illustration of the need for caution in 
the use of pharmacological agents to elucidate hormone 
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mechanisms relates to the calcium antagonists D-600 
and verapamil. These have also been shown to inhibit 
the binding of o-agonists to their receptors [ 1 O-l 21. 
Here, we report that chlorpromazine and trifluo- 
perazine inhibit the actions of ar-adrenergic agonists in 
hepatocytes, but not those of glucagon, vasopressin 
and A23 187. Like a-agonists, the latter two agents 
have been demonstrated to be dependent on Ca*+ 
for their actions [ 13 1. It is also shown that the two 
antipsychotic drugs inhibit the binding of [3H]epine- 
phrine to cr-adrenergic sites in liver plasma membranes. 
It is therefore proposed that the inhibition of (Y- 
adrenergic effects in the liver by chlorpromazine and 
trifluoperazine [7,8] isexplicable in terms ofan effect 
at the a-adrenergic receptor and that a role for calmo- 
duiin should not be inferred from experiments using 
these agents alone. 
2. Materials and methods 
Methods for the isolation and incubation of hepa- 
tocytes have been described [14]. Phosphorylase a, 
glycogen synthase and cellular calcium content were 
determined in 0.5 ml aliquots of cell suspension as 
detailed in [13,14]. Binding of [3H]epinephrine to 
rat liver plasma membranes was measured as in 
[ 10,151. Trifluoperazine and chlorpromazine were 
gifts from Smith, Kline and French. 
3. Results and discussion 
Effect of chlorpromazine on phenylephrine-induced 
activation of phosphorylase and calcium efflux 
The results in fig.1 show that lo-’ M chlorpro- 
mazine completely inhibits IO6 M phenylephrine 
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Fig.1. Effect of chlorpromazine on phosphorylase activation 
and calcium eftlux induced by phenylephrine. Rat liver cells 
were incubated in the presence of various concentrations of 
chlorpromazine and in the presence of phenylephnne (Phe 
1 Oe6 M) or saline (control). After a 5 min incubation, aliquots 
of cells were taken for measurement of phosphorylase a and 
calcium content. Units of phosphorylase are defined as pmol 
[‘4CJglucose-l-P incorporated into glycogen min-’ g wet 
wt cells-‘. Results are means of 3 expt performed in duplicate 
and are given f SEM. 
action on phosphorylase activation and calcium efflux 
in hepatocytes. A half-maximal effect of chlorproma- 
zine is observed at -5 X 10” M. This inhibitory ac- 
tion of chlorpromazine on phenylephrine effects is 
also observed at several concentrations of phenyleph- 
rine (fig.2). 
As outlined in section 1, chlorpromazine not only 
inhibits calmodulin-mediated actions, but also has 
effects at the brain a-adrenergic receptor. Thus it can 
not be concluded from these results (fig.l,2) where 
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Fig.2. Effect of chlorpromazine on the dose-response of 
phenylephrineinduced changes in phosphorylase and calcium 
content. Liver cells were incubated in the presence of various 
concentrations of phenylephrine in the presence and absence 
of chlorpromazine (CPZ 1 0v5 M). After a 5 min incubation, 
aliquots of cells were removed for measurement of phos- 
phorylase 0 and calcium. Results are means of 3 expt per- 
formed in duplicate and are given f SFM. 
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Frg.3. Effect of chlorpromazme on the dose response of vas- 
opressin on phosphorylase activation and calcium content. 
Liver cells were incubated in the presence of various concen- 
trations of vasopressin in the presence and absence of chlor- 
promazine (10e5 M). See legend of fig.2 for other details. 
chlorpromazine is acting. One additional experimen- 
tal approach is to use agents which elicit the same 
responses as a-adrenergic agonists in a Ca*+-dependent 
manner, but do not act via the o-receptor. Two such 
agents are vasopressin and the divalent cationophore 
A23187 [13,16]. 
The results in fig.3,4 show that IO-’ M chlorpro- 
mazine does not inhibit the effects of vasopressin 
and A23 187 on calcium fluxes and phosphorylase 
activation in hepatocytes. These findings indicate 
that it is invalid to attribute the inhibitory effect of 
the phenothiazine on a-adrenergic responses to an 
interaction with calmodulin [7,8]. Chlorpromazine 
also did not modify phosphorylase activation by glu- 
cagon, an agent which acts in a Ca*+-independent 
manner in hepatocytes [ 171 (not shown). In confir- 
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Fig.4. Effect of chlorpromazine on the dose response of 
A23187 on phosphorylase activation and calcium content. 
See legend of fig.2 for other details. 
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mation of earlier results, glucagon (1 0m9 M) had mini- 
mal effects on Ca*+ efflux from liver cells (not shown) 
[10,13,16-181 and chlorpromazine did not have any 
effect by itself or in combination with glucagon [7,8]. 
In summary, the above studiessuggest that the unique 
inhibitory action of chlorpromazine on the actions of 
a-adrenergic agonists can be explained in terms of 
inhibition of binding at the cy-adrenergic receptor 
[4-61. To establish that this is indeed the case, com- 
petitive binding experiments were performed using 
partially purified rat liver plasma membranes. The 
results in fig.5 show that trifluoperazine inhibits spe- 
cific binding of [3H]epinephrine to a-adrenergic 
receptors. Epinephrine binding to isolated plasma 
membranes has been demonstrated to be correlated 
directly with phosphorylase activation and Ca2+ efflux 
in isolated hepatocytes [ 151. The results in fig.5 also 
show a good correlation between trifluoperazine inhi- 
bition of epinephrine activation of phosphorylase and 
epinephrine binding. Half-maximal inhibition of both 
binding and phosphorylase activation is seen at -3 X 
Fig.5. Displacement of (t)-[3Hlepinephrine bound to plasma 
membranes and inhibition of epinephrine induced activation 
of phosphorylase bytrifluoperazine. Incubations for the dis- 
placement of 50 nM (+)-[3H]epinephrine by trifluoperazine 
were carried out in duplicate and each incubation yielded 2 
determinations. Inhibition of 100% is that produced by 10 MM 
phenouybenzamine. Data shown are from representative ex- 
periments, each experiment was carried out at least twice. 
The inhibition by trifluoperazine of phosphorylase activation 
caused by 50 nM epinephrine was measured after 5 min incu- 
bation. Control and epinephrine-stimulated phosphorylase (I 
levels were 15 and 22 units, respectively. Each point is the 
mean of 6 expt performed in duplicate. 
IO-’ M tritluoperazine. Chlorpromazine has similar 
inhibitory effects on epinephrine binding and phos- 
phorylase activation (not shown). 
Liver contains a calmodulin-dependent glycogen 
synthase kinase [ 191. The following experiments were 
designed to show whether such kinases were involved 
in hormonal control of glycogen synthase in liver. No 
effect on the inactivation of glycogen synthase by 
A23 187 (1 Om6 M) and vasopressin (250 ~U/ml) was 
observed with chlorpromazine, trifluoperazine and 
fluphenazine at 1 O6 --lo-’ M (not shown). When 
chlorpromazine (1 O-’ M) was incubated with varying 
concentrations of vasopressin and A23 187 there was 
also no inhibition of the inactivation of glycogen syn- 
thase (fig.6). Varying the time of preincubation with 
the phenothiazines from 1-l 0 min did not alter the 
results (not shown). 
Trifluoperazine at lo-’ M has been shown to com- 
pletely inactivate the calmodulin-dependent synthase 
kinase in vitro [ 191, hence if this kinase were respon- 
sible for the inactivation of glycogen synthase then 
one might have expected to see an effect. The uptake 
of chlorpromazine by liver cells does not appear to 
be a rate-limiting step for its action since hepatocytes 
have been shown to both absorb and adsorb this agent 
by unsaturable processes [21]. However since the 
phenothiazines are strong cationic surfactants they 
may adsorb onto intracellular cell membranes and 
hence the free intracellular concentration may be 
lower than expected. In addition, they are readily 
metabolized in the liver [22]. 
These results show that phenothiazines act as 
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Fig.6. Effect of chlorpromazine on the dose-response of 
vasopressin and A23 187 inactivation of glycogen synthase. 
Cells were preincubated for 7 min with 30 mM glucose and 
chlorpromazine (I 0“ M), then either A23 I87 or vasopressin 
was added and the incubation continued for a further 5 min. 
Aliquots of cells (I ml) were removed and rapidly frozen in 
liquid N, and assayed as in [ 14,201. Each point is the mean 
of 2 expt performed in duplicate. 
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a-adrenergic antagonists and that they have little or 
no effect on the ability of A23 187, vasopressin and 
glucagon to activate phosphorylase,inactivate glycogen 
synthase or elicit Ca*+efflux in hepatocytes. Although 
the plasma membrane does not appear to limit the 
penetration of phenothiazines, the intracellular con- 
centration of these agents may not reach a level that 
will inhibit calmodulin-dependent processes due to 
metabolism or binding to membranes. Furthermore, 
they may not interact as readily with calmodulin 
when this is the subunit of an enzyme [23]. In the 
same context, the binding of 50 nM (*)-[3H]epineph- 
rine to isolated plasma membranes is not modified by 
0.1 mM EGTA or by 0.1 mM Ca*+ or 1 O-’ M calmo- 
dulin prepared according to [24] added either singly 
or in combination (not shown). Taking all of these 
points into consideration it would appear that an 
examination of the effects of phenothiazines in intact 
cells may not provide valid information concerning 
the role of calmodulin in certain responses [7,8]. In 
particular, the fact that these drugs interact with 
cr-adrenergic receptors renders invalid their use in 
studies exploring the role of calmodulin in a-adrener- 
gic responses. Until more specific inhibitors of calmo- 
dulin in action are found the question remains unan- 
swered regarding the involvement of calmodulin in 
these and other hepatic responses. This study stresses 
the point we made in [lo] that caution should be used 
when pharmacological agents with properties charac- 
terized for one system are used in studies or other 
systems. 
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